Michael Moran, PhD

Dr. Moran completed his doctoral training at the National Cancer Institute of Canada's Cancer Research laboratory, University of Western Ontario, and then spent four years as an NCIC Fellow at Mount Sinai Hospital, Toronto. He was appointed as a faculty member at the University of Toronto in 1990 and granted tenure in 1995. He has held career awards from both the NCIC and Canadian Institutes of Health Research.

During an extended sabbatical leave in 2000-2003 Dr. Moran co-founded of the drug discovery company MDS Proteomics. He currently holds a Tier 1 Canada Research Chair in Biochemistry/Molecular Therapeutics.
Dr. Moran's pioneering research program in focused on areas of cell regulation and proteomics. His current research involves using mass spectrometry, in which proteins are converted into ion beams, to determine their structures. By this approach Dr. Moran aims to comprehensively profile and classify tumours according to their proteins and activated signaling networks. The goal of this research is to facilitate the discovery of new, innovative cancer treatments.

For a list of Dr. Moran’s publications, please visit PubMed or Scopus.

Professor, Department of Molecular Genetics, University of Toronto